This type of acquired resistance has been seen in lung tumors, where resistance to EGFR inhibitors (EGFRi) was associated with compensatory up-regulation of HER3, and combining EGFR and HER3 inhibitions led to improved anti-cancer effects compared to EGFRi alone [37]. This evidence concerns the gene ERBB3 and cancer.